Health Care [ 8/12 ] | Biotechnology [ 34/74 ]
NASDAQ | Common Stock
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States.
It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
The company's product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases.
It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin's lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases.
The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells.
The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018.
Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 25 | -0.23 Increased by +43.90% | -0.24 Increased by +5.27% |
| Nov 6, 24 | -0.25 Decreased by -1.35 K% | -0.27 Increased by +7.41% |
| Aug 8, 24 | -0.32 Increased by +45.76% | -0.28 Decreased by -14.29% |
| May 8, 24 | -0.32 Increased by +25.58% | -0.32 |
| Feb 29, 24 | -0.41 Decreased by -7.89% | -0.38 Decreased by -7.89% |
| Nov 8, 23 | 0.02 Increased by +104.44% | -0.45 Increased by +104.44% |
| Aug 3, 23 | -0.59 Decreased by -51.28% | -0.43 Decreased by -37.21% |
| May 8, 23 | -0.43 Increased by +8.51% | -0.45 Increased by +4.44% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by N/A% | -49.07 M Increased by +44.31% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -59.92 M Decreased by -6.19 K% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -50.29 M Increased by +55.88% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -107.47 M Decreased by -34.02% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -88.12 M Decreased by -12.36% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | 984.00 K Increased by +101.17% | Increased by +N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -114.00 M Decreased by -58.71% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -80.19 M Decreased by -156.94% | Decreased by N/A% Decreased by N/A% |